Aeolus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Press Release Source: Aeolus Pharmaceuticals On Wednesday November 9, 2011, 9:05 am EST
MISSION VIEJO, CA--(Marketwire -11/09/11)- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS.OB - News) (Pinksheets:AOLS.OB - News), a biotechnology company leveraging significant government funding to develop a platform of novel compounds in oncology and biodefense, today announced that it will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will take place November 15 and 16 at the Pierre Hotel in New York.
The Company will be presenting on November 16 at 1:30 p.m. EST in the Salon Room. The presentation will be webcast and is available through the investor relations section of the Company's website at www.aeoluspharma.com. The format of the event is a short company presentation followed by a conversation and Q&A with a Lazard life science analyst.
Aeolus will also host one-on-one meetings with members of the professional community in New York on November 15, 16 and 17. Investors can schedule a meeting with the Company by contacting Russell Skibsted at or by scheduling a meeting through the one-on-one desk at Lazard.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118 million, to efficiently develop the compound for use in oncology.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' amended Annual Report on Form 10-K/A for the year ended September 30, 2010. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.